Literature DB >> 23540694

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Florian Klein1, Ron Diskin, Johannes F Scheid, Christian Gaebler, Hugo Mouquet, Ivelin S Georgiev, Marie Pancera, Tongqing Zhou, Reha-Baris Incesu, Brooks Zhongzheng Fu, Priyanthi N P Gnanapragasam, Thiago Y Oliveira, Michael S Seaman, Peter D Kwong, Pamela J Bjorkman, Michel C Nussenzweig.   

Abstract

Broadly neutralizing antibodies (bNAbs) to HIV-1 can prevent infection and are therefore of great importance for HIV-1 vaccine design. Notably, bNAbs are highly somatically mutated and generated by a fraction of HIV-1-infected individuals several years after infection. Antibodies typically accumulate mutations in the complementarity determining region (CDR) loops, which usually contact the antigen. The CDR loops are scaffolded by canonical framework regions (FWRs) that are both resistant to and less tolerant of mutations. Here, we report that in contrast to most antibodies, including those with limited HIV-1 neutralizing activity, most bNAbs require somatic mutations in their FWRs. Structural and functional analyses reveal that somatic mutations in FWR residues enhance breadth and potency by providing increased flexibility and/or direct antigen contact. Thus, in bNAbs, FWRs play an essential role beyond scaffolding the CDR loops and their unusual contribution to potency and breadth should be considered in HIV-1 vaccine design.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23540694      PMCID: PMC3792590          DOI: 10.1016/j.cell.2013.03.018

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  60 in total

1.  IMGT, the international ImMunoGeneTics database.

Authors:  M P Lefranc; V Giudicelli; C Ginestoux; J Bodmer; W Müller; R Bontrop; M Lemaitre; A Malik; V Barbié; D Chaume
Journal:  Nucleic Acids Res       Date:  1999-01-01       Impact factor: 16.971

Review 2.  The targeting of somatic hypermutation.

Authors:  C J Jolly; S D Wagner; C Rada; N Klix; C Milstein; M S Neuberger
Journal:  Semin Immunol       Date:  1996-06       Impact factor: 11.130

Review 3.  AID targeting in antibody diversity.

Authors:  Rushad Pavri; Michel C Nussenzweig
Journal:  Adv Immunol       Date:  2011       Impact factor: 3.543

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

6.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

7.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

8.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

9.  Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.

Authors:  John Pietzsch; Johannes F Scheid; Hugo Mouquet; Florian Klein; Michael S Seaman; Mila Jankovic; Davide Corti; Antonio Lanzavecchia; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

10.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

View more
  292 in total

Review 1.  Clonal and cellular dynamics in germinal centers.

Authors:  Gabriel D Victora; Luka Mesin
Journal:  Curr Opin Immunol       Date:  2014-03-27       Impact factor: 7.486

Review 2.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

Review 3.  What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection?

Authors:  Christopher T Stamper; Patrick C Wilson
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

4.  Determinants of HIV-1 broadly neutralizing antibody induction.

Authors:  Peter Rusert; Roger D Kouyos; Claus Kadelka; Hanna Ebner; Merle Schanz; Michael Huber; Dominique L Braun; Nathanael Hozé; Alexandra Scherrer; Carsten Magnus; Jacqueline Weber; Therese Uhr; Valentina Cippa; Christian W Thorball; Herbert Kuster; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Jacques Fellay; Roland R Regoes; Huldrych F Günthard; Alexandra Trkola
Journal:  Nat Med       Date:  2016-09-26       Impact factor: 53.440

5.  AIDS/HIV. Host controls of HIV neutralizing antibodies.

Authors:  Barton F Haynes; Laurent Verkoczy
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

6.  Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.

Authors:  Mikyung Kim; Likai Song; James Moon; Zhen-Yu J Sun; Anna Bershteyn; Melissa Hanson; Derek Cain; Selasie Goka; Garnett Kelsoe; Gerhard Wagner; Darrell Irvine; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

7.  Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.

Authors:  Karen Tran; Christian Poulsen; Javier Guenaga; Natalia de Val; Natalia de Val Alda; Richard Wilson; Christopher Sundling; Yuxing Li; Robyn L Stanfield; Ian A Wilson; Andrew B Ward; Gunilla B Karlsson Hedestam; Richard T Wyatt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

8.  The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses.

Authors:  Chun Chou; Daniel J Verbaro; Elena Tonc; Melanie Holmgren; Marina Cella; Marco Colonna; Deepta Bhattacharya; Takeshi Egawa
Journal:  Immunity       Date:  2016-08-23       Impact factor: 31.745

9.  Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

Authors:  Daniel T MacLeod; Nancy M Choi; Bryan Briney; Fernando Garces; Lorena S Ver; Elise Landais; Ben Murrell; Terri Wrin; William Kilembe; Chi-Hui Liang; Alejandra Ramos; Chaoran B Bian; Lalinda Wickramasinghe; Leopold Kong; Kemal Eren; Chung-Yi Wu; Chi-Huey Wong; Sergei L Kosakovsky Pond; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Authors:  Till Schoofs; Florian Klein; Malte Braunschweig; Edward F Kreider; Anna Feldmann; Lilian Nogueira; Thiago Oliveira; Julio C C Lorenzi; Erica H Parrish; Gerald H Learn; Anthony P West; Pamela J Bjorkman; Sarah J Schlesinger; Michael S Seaman; Julie Czartoski; M Juliana McElrath; Nico Pfeifer; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.